title: [Efficacy and safety of rituximab combined with CHOP or combined with dose fractionated CHOP in the treatment of primary gastric diffuse large B cell lymphoma].
abstract: OBJECTIVE
  The aim of this study was to compare the safety and efficacy profiles of R-CHOP and R-fCHOP regimes in the treatment of primary gastric diffuse large B cell lymphoma (PG-DLBCL).
  
  
  METHODS
  Data of PG-DLBCL patients admitted in our hospital from March 2010 to March 2014 were collected retrospectively. Differences in gastrointestinal bleeding and perforation between the R-CHOP group and R-fCHOP group were compared. The influence of the gastrointestinal complication on subsequent treatment was also analyzed. Treatment outcome of the two groups was also compared.
  
  
  RESULTS
  A total of 50 patients were included in this retrospective study. Forty of them were in the R-CHOP group, another ten were in the R-fCHOP group. Patients in the R-fCHOP group had a higher rate of Lugano late stage disease, and a relatively high rate of a deeper/larger ulcer. Fence occult blood test (FOBT) was positive in one (10.0%) patient in the R-fCHOP group, and 11 (31.4%) patients in the R-CHOP group, among them one had hematemesis and had to give up the subsequent chemotherapy. No perforation was observed in both groups. The response rate (RR) was 92.5% in the R-CHOP group and 90.0% in the R-fCHOP group (P > 0.05). The PFS was also comparable between the two groups (P > 0.05).
  
  
  CONCLUSIONS
  R-fCHOP regimen has a good safety profile in patients with Lugano late stage and deep/large ulcers, who are of high risk of gastrointestinal bleeding or perforation, and also has a comparable efficacy profile when compared with the R-CHOP regimen in short-term follow-up.
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Dongmei
authors.initials: D
authors.lastname: Ji
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Hong
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Xue
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Qunling
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Weina
authors.initials: W
authors.lastname: Shen
authors.affiliation: Department of Medical Oncology, Cancer Hospital; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. Email: cao_junning@hotmail.com.
authors.forename: Junning
authors.initials: J
authors.lastname: Cao
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004317:Doxorubicin; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin; D008297:Male; D008875:Middle Aged; D011241:Prednisone; D012189:Retrospective Studies; D000069283:Rituximab; D013274:Stomach Neoplasms; D016896:Treatment Outcome; D014750:Vincristine
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone